Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Current Liabilities (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Total Current Liabilities data on record, last reported at $50.1 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 16.13% year-over-year to $50.1 million; the TTM value through Sep 2025 reached $50.1 million, up 16.13%, while the annual FY2024 figure was $45.8 million, 4.04% down from the prior year.
  • Total Current Liabilities reached $50.1 million in Q3 2025 per SGMO's latest filing, up from $47.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $136.9 million in Q2 2021 and bottomed at $39.0 million in Q2 2024.
  • Average Total Current Liabilities over 5 years is $80.3 million, with a median of $53.8 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: surged 114.03% in 2021, then tumbled 60.38% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $127.9 million in 2021, then fell by 12.65% to $111.7 million in 2022, then crashed by 57.27% to $47.7 million in 2023, then decreased by 4.04% to $45.8 million in 2024, then increased by 9.43% to $50.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $50.1 million in Q3 2025, $47.7 million in Q2 2025, and $49.6 million in Q1 2025.